About article
Validation and Assessment of Osteoporosis Self-Efficacy Among Iraqi General Population
Background: Poor quality of life, fractures and disability are the consequences of preventable osteoporosis. Objectives: The aims of this study were to validate and assess Osteoporosis Self-efficacy Scale (OSES-A) Arabic version among Iraqi general population. Methods: A cross-sectional study with a random cluster sampling method from the community was used. Forward-backward-forward translation method was used to translate the questionnaire from English to Arabic. Beside OSES-A, Osteoporosis Knowledge Tool (OKT) and Osteoporosis Health Belief Scale (OHBS) Arabic versions were used to assess osteoporosis preventive behaviours. Results: The results showed good face validity and reliability. The construct validity showed two factors which explain 80.86% of the variance. In addition, the result showed low self-efficacy score (658.43+/-222.014) with 83.33% were found to have low OSES-A level. There were significant associations between age, gender, and self-reported osteoporosis with OSES-A levels. In addition, there were significant differences between age, gender, marital status, family history of osteoporosis, self-reported osteoporosis and osteoporosis diagnosis or screening in relation to total OSES-A scores. Moreover, there were positive correlations between the OSES-A total score with total knowledge and health belief. Multivariate analysis revealed that OKT levels, OHBS levels, age and gender were predictors for OSES-A levels. Conclusion: This study showed good cultural adaptation and psychometric properties of OSES-A tool and could be used in any osteoprotective educational program.
Sahib MN. Validation and Assessment of Osteoporosis Self-Efficacy Among Iraqi General Population. The open nursing journal. 2018;12:76-85.
Methods | Condition | Gender | Age | Country | Setting | Sample size |
---|---|---|---|---|---|---|
|
healthy | Both | 18 - 87 |
Iraq |
Commuinty | 355 |
Measure does not require training
Less than 5 min
mohanad_pharm@yahoo.com